checkAd

     129  0 Kommentare Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2020 Financial Results - Seite 2

    Forward-Looking Statement

    Statements herein the terms “believes”, “intends”, “projects”, “anticipates”, “expects”, and similar expressions as used are intended to reflect “forward-looking statements” of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements or paragraphs, many of which are outside the control of the Company. These uncertainties and other factors include the impact of the COVID-19 pandemic on our sales, operations and supply chain, the success of the Company’s global expansion initiatives and product diversification, the Company’s actual future ownership stake in future therapies emerging from its collaborative research partnerships, the success related to its IP portfolio, the Company’s future competitive position in stem cell innovation, future success of its core business and the competitive impact of public cord blood banking on the Company’s business, the Company’s ability to minimize future costs to the Company related to R&D initiatives and collaborations and the success of such initiatives and collaborations, the success and enforceability of the Company’s menstrual stem cell technology license agreements and umbilical cord blood license agreements and their ability to provide the Company with royalty fees, the ability of the reproductive tissue storage to generate new revenues for the Company and those risks and uncertainties contained in risk factors described in documents the Company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any Current Reports on Form 8-K filed by the Company. The Company disclaims any obligations to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements.

    Contact:

    David Portnoy
    Chairman and Co-Chief Executive Officer
    Cryo-Cell International, Inc.
    813-749-2100
    dportnoy@cryo-cell.com 

    Seite 2 von 2




    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2020 Financial Results - Seite 2 OLDSMAR, Fla., April 14, 2020 (GLOBE NEWSWIRE) - Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the …